Express Mail Label Number

Address to:

MS: Patent Application Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **divisional** of prior Application No. 10/180,289, filed June 26, 2002.

Appli	cant	(or identifier):	ALTMANN ET AL.						
Title:			VEGF RECEPTOR TYROSINE KINASE INHIBITORS						
Encl	osed	are:							
1. 2. 3.		Drawings - Declaration and a. Newly b. Copy signed i. Si ap	eletion of Inventors gned statement attached deleting inventor(s) named in the prior eplication						
4.		and Power of A	osure of the prior application, from which a copy of the Declaration attorney is supplied under Box 3b, is considered as being part of the e accompanying application and is hereby incorporated by						
5. 6.		Microfiche Con Nucleotide and Computer Paper Cop	nputer Program (appendix) /or Amino Acid Sequence Submission Readable Copy						
7. 8. 9. 10. 11. 12.		Preliminary Am Assignment Pa English Transla Information Dis Certified Copy Return Receipt	endment pers (Cover Sheet & Document(s)) ation of closure Statement of Priority Document(s)						
\boxtimes	App requ	The right to elect an invention or species that is different from that elected in parent Application No. 10/180,289 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.							
Filing	j fee	calculation:							
			ne filing fee, please enter the enclosed Preliminary Amendment.						

Basic Filing Fee										
Multiple Dependent Claim Fee (\$ 290)										
Foreign Language Surcharge (\$ 900)										
	For	Number Filed		Number Extra		Rate				
Extra Claims	Total Claims	17	-20	О	×	\$	18	=	\$	
	Independent Claims	2	-3	0	×	\$	86	=	\$	
TOTAL FILING FEE										

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$770. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

Date: April 21, 2004

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (973) 781-8064.

Respectfully submitted,

Lyd M. Nally Lydia T. McNally

Attorney for Applicants

Reg. No. 36,214

Tel. No. (862) 778-7898